ESSA Pharma Inc.
ESSA Pharma Inc.:
Focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. EPI-7386 is currently being studied in a Ph 1 clinical trial in men with metastatic castration-resistant prostate cancer whose tumors have progressed on current standard-of-care therapies. Initial data for Ph 1 monotherapy study of EPI-7386 is expected in 1H 2022. The company has also established clinical collaborations with JNJ, Astellas, and Bayer to evaluate EPI-7386 in combination with conventional anti-androgens. Combo trials remain on track to begin in Q4 2021 with RP2D already established.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
North America
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Men's Health, Oncology
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
999 West Broadway Street Suite 720
Vancouver, BC BC V5Z 1K5
Canada
Vancouver, BC BC V5Z 1K5
Canada
More info:
My account:
Company Participants at Solebury Trout Virtual Management Access Event 2021
David Parkinson
ESSA Pharma Inc., President/CEO
Dr. Parkinson has been ESSA’s President and Chief Executive Officer since 2016 and has been a member of ESSA’s Board of Directors since 2015. Dr. Parkinson has more than 30 years of experience in clinical oncology development. Prior to joining ESSA, Dr. Parkinson was a Venture Partner at New Enterprise Associates, Inc. and served as the President and CEO of Nodality, Inc., a biotechnology company developing human cell-based translational diagnostic tools. Throughout his career, Dr. Parkinson has held senior roles in clinical oncology development at a number of pharmaceutical and biotech companies, including Biogen, Amgen and Novartis, and has overseen the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara, and Vectibix. Dr. Parkinson currently serves as Director on the Boards of CTI Biopharma, Inc. and 3SBio Inc and is a Co-Founder and Director of Refuge Biotechnology, Inc. Dr. Parkinson has held academic positions at Tufts and the University of Texas MD Anderson Cancer Center, has authored over 100 peer-reviewed publications and is a recipient of the FDA’s Cody Medal. Dr. Parkinson received an M.D. from the University of Toronto.
Top 10 Holders of ESSA Pharma Inc
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Bellevue Asset Management AG | 11.45 | 5,034,814 | 46.92 | 13F | 9/30/21 |
| Janus Henderson Group Plc (Subfiler) | 7.91 | 3,477,844 | 32.41 | 13F | 9/30/21 |
| Clarus Ventures LLC | 7.51 | 3,303,103 | 30.78 | 13F | 9/30/21 |
| Soleus Capital Management LP | 6.52 | 2,868,023 | 26.73 | 13F | 9/30/21 |
| BVF, Inc. | 6.48 | 2,851,461 | 26.58 | 13F | 9/30/21 |
| RTW Investments LP | 6.00 | 2,637,192 | 24.58 | 13F | 9/30/21 |
| Avidity Partners Management LP | 5.57 | 2,450,000 | 22.83 | 13F | 9/30/21 |
| Eventide Asset Management LLC | 4.96 | 2,181,101 | 20.33 | 13F | 9/30/21 |
| Adage Capital Partners GP LLC | 3.51 | 1,542,531 | 14.38 | 13F | 9/30/21 |
| Vivo Capital LLC | 2.40 | 1,056,067 | 9.84 | 13F | 9/30/21 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.